CD30biAb-AATC for CD30+ Malignancies
Conditions: Pediatric Cancer; Hodgkin Disease; CD30-Positive Diffuse Large B-Cell Lymphoma; CD30+ Anaplastic Large Cell Lymphoma; CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma; CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma; Neuroblastoma; Germ Cell Tumor, Ext ragonadal; Chondrosarcoma; Leukemia; Solid Tumor; Lymphoma Intervention: Drug: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) Sponsors: Medical College of Wisconsin; Midwest Athletes Against Childhood Cancer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer | Cancer & Oncology | Chondrosarcoma | Leukemia | Lymphoma | Neuroblastoma | Neurology | Pediatrics | Research